Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.690
-0.080 (-1.68%)
At close: Apr 28, 2026, 4:00 PM EDT
4.660
-0.030 (-0.64%)
After-hours: Apr 28, 2026, 4:42 PM EDT
Bicycle Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Bicycle Therapeutics stock have an average target of 13.9, with a low estimate of 7.00 and a high estimate of 36. The average target predicts an increase of 196.38% from the current stock price of 4.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicycle Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $13 → $12 | Hold | Maintains | $13 → $12 | +155.86% | Apr 8, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $44 → $36 | Buy | Maintains | $44 → $36 | +667.59% | Mar 18, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $11 → $7 | Hold | Maintains | $11 → $7 | +49.25% | Mar 18, 2026 |
| Citizens | Citizens | Buy Maintains $12 → $8 | Buy | Maintains | $12 → $8 | +70.58% | Mar 18, 2026 |
| Needham | Needham | Strong Buy Maintains $24 → $15 | Strong Buy | Maintains | $24 → $15 | +219.83% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
33.82M
from 72.59M
Decreased by -53.41%
Revenue Next Year
25.03M
from 33.82M
Decreased by -25.97%
EPS This Year
-2.22
from -3.16
EPS Next Year
-2.13
from -2.22
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 75.6M | ||||||
| Avg | 33.8M | 25.0M | ||||||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -13.2% | 123.6% | ||||||
| Avg | -53.4% | -26.0% | ||||||
| Low | -79.7% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.37 | -0.74 | ||||||
| Avg | -2.22 | -2.13 | ||||||
| Low | -2.92 | -3.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.